Wuxi Biologics Co. Ltd. and Sinorda Biomedicine have established a strategic collaboration for the development and manufacturing of SND-006, a novel bispecific antibody, for the treatment of ...
WuXi Biologics and Sinorda Biomedicine collaborate to accelerate development and manufacturing of innovative bispecific antibody: Shanghai Friday, January 30, 2026, 10:00 Hrs [IST ...
WuXi Biologics and Sinorda Biomedicine have jointly announced a strategic collaboration for the development and manufacturing ...
Lonza Group stock is a top CDMO benefiting from biopharma outsourcing, strong growth, and expanding margins. Learn more about ...
China-based biologics services group WuXi Biologics (HKG: 2269) has entered a strategic collaboration with Sinorda ...
This edition of the Belt and Road Monitor covers 1st to 31st December 2025 - China Russia and BRI project developments ...
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and ...
In December 2025, the domestically produced Butantan-DV vaccine was approved by Brazil's regulatory agency for use in individuals aged 12–59 years. Marcia Triunfol reports.
HanchorBio and WuXi Biologics collaborate to develop fusion proteins using the Fc-Based Designer Biologics platform, targeting oncology and autoimmune diseases. WuXi Biologics offers end-to-end ...
WuXi Biologics is increasing strategic investments in the U.S. to deliver integrated biologics services. By leveraging ...
Despite new methodologies and flexible regulatory pathways, CNS biopharmaceuticals still face significant safety assessment ...
Taiwanese biotech HanchorBio (TPEx: 7827) has signed a strategic collaboration with WuXi Biologics (HKEX: 2269) to develop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results